Related Experiment Video
Updated: Mar 26, 2026
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Anticoagulation Therapy in Traumatic Brain Injury
Tomasz Tykocki1, Krystyna Guzek2
1Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland.
Insights
Managing anticoagulation therapy (AT) after traumatic brain injury (TBI) is complex. New oral anticoagulants show a lower risk of intracranial hemorrhage compared to warfarin in TBI patients.
Area of Science:
- Neurology
- Neurosurgery
- Pharmacology
Background:
- Anticoagulation therapy (AT) management in traumatic brain injury (TBI) is challenging.
- Limited data exist, necessitating expert opinion for clinical decisions.
- Perioperative AT and antiplatelet strategies require critical assessment.
Purpose of the Study:
- To critically evaluate therapeutic options for anticoagulation and antiplatelet agents in the perioperative period following TBI.
- To summarize current evidence regarding anticoagulation management in TBI patients.
Main Methods:
- A comprehensive literature review was conducted.
- Relevant data on anticoagulation therapy in TBI patients were summarized.
Main Results:
- Patients on preinjury AT with TBI face risks of thromboembolic complications and hematoma expansion.
- New oral anticoagulants (NOACs) demonstrate a lower incidence of intracranial hemorrhage than warfarin.
- Intracranial hemorrhage rates are significantly lower with NOACs or heparin compared to vitamin K antagonists.
Conclusions:
- NOACs may represent a safer alternative to warfarin in TBI patients requiring anticoagulation.
- Further research is needed to establish optimal AT protocols for TBI.
- Careful consideration of anticoagulation strategies is crucial for improving outcomes in TBI patients.
Background:
Optimal anticoagulation therapy (AT) in patients with traumatic brain injury (TBI) is a challenging task and proper management is strongly correlated with clinical outcomes. Only limited data are available on AT after TBI and practical decision making is based on the opinion of experts. This review sought to critically assess different therapeutic options using AT and antiplatelet agents in the perioperative period after TBI.
Methods:
A comprehensive review of the literature was performed to summarize relevant data on AT in patients with TBI.
Results:
Patients with preinjury AT with TBI require emergent neurosurgical treatment and they are also at high risk of developing thromboembolic complications or hematoma expansion. New oral anticoagulants offer a lower incidence of intracranial hemorrhage compared with warfarin. The rate of intracranial hemorrhage during new oral anticoagulants or heparin therapy is significantly lower than that with vitamin K antagonists.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis IV: Nursing Management